Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AUPH NASDAQ:AXSM NASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$88.03+2.9%$51.77$4.77▼$92.91$6.65B0.58959,392 shs3.20 million shsAUPHAurinia Pharmaceuticals$12.40-1.0%$10.28$6.42▼$12.82$1.63B1.261.79 million shs1.83 million shsAXSMAxsome Therapeutics$125.17+0.6%$110.23$75.56▼$139.13$6.25B0.54510,939 shs506,617 shsRNAAvidity Biosciences$50.36+3.9%$39.24$21.51▼$56.00$6.48B0.992.36 million shs7.39 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.90%+8.64%+27.41%+974.85%+618.03%AUPHAurinia Pharmaceuticals-1.04%+3.42%+6.80%+51.40%+77.65%AXSMAxsome Therapeutics+0.61%+3.21%+21.22%+11.85%+30.99%RNAAvidity Biosciences+3.90%+8.12%+4.35%+38.96%+20.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$88.03+2.9%$51.77$4.77▼$92.91$6.65B0.58959,392 shs3.20 million shsAUPHAurinia Pharmaceuticals$12.40-1.0%$10.28$6.42▼$12.82$1.63B1.261.79 million shs1.83 million shsAXSMAxsome Therapeutics$125.17+0.6%$110.23$75.56▼$139.13$6.25B0.54510,939 shs506,617 shsRNAAvidity Biosciences$50.36+3.9%$39.24$21.51▼$56.00$6.48B0.992.36 million shs7.39 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.90%+8.64%+27.41%+974.85%+618.03%AUPHAurinia Pharmaceuticals-1.04%+3.42%+6.80%+51.40%+77.65%AXSMAxsome Therapeutics+0.61%+3.21%+21.22%+11.85%+30.99%RNAAvidity Biosciences+3.90%+8.12%+4.35%+38.96%+20.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.13Buy$92.334.89% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$12.00-3.23% DownsideAXSMAxsome Therapeutics 3.13Buy$177.8642.09% UpsideRNAAvidity Biosciences 3.06Buy$67.0033.04% UpsideCurrent Analyst Ratings BreakdownLatest AUPH, ABVX, AXSM, and RNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$163.008/8/2025RNAAvidity BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$70.00 ➝ $75.008/8/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$59.00 ➝ $62.008/8/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$173.00 ➝ $176.008/5/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$184.00 ➝ $189.008/4/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$150.008/1/2025AUPHAurinia PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $9.007/30/2025AUPHAurinia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.007/29/2025ABVXAbivaxPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$70.00 ➝ $112.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAUPHAurinia Pharmaceuticals$235.13M6.94$0.31 per share40.20$2.68 per share4.63AXSMAxsome Therapeutics$385.69M16.19N/AN/A$1.18 per share106.08RNAAvidity Biosciences$10.90M594.39N/AN/A$11.94 per share4.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AAUPHAurinia Pharmaceuticals$5.75M$0.4328.8422.14N/A23.31%20.06%13.81%11/6/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.07N/A44.39N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)Latest AUPH, ABVX, AXSM, and RNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million7/31/2025Q2 2025AUPHAurinia Pharmaceuticals$0.17$0.16-$0.01$0.16$64.27 million$70.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25AUPHAurinia Pharmaceuticals0.185.234.63AXSMAxsome Therapeutics1.661.571.51RNAAvidity BiosciencesN/A9.269.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AUPHAurinia Pharmaceuticals36.83%AXSMAxsome Therapeutics81.49%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAUPHAurinia Pharmaceuticals12.20%AXSMAxsome Therapeutics22.30%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableAUPHAurinia Pharmaceuticals300131.63 million115.57 millionOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableRNAAvidity Biosciences190128.65 million123.73 millionOptionableAUPH, ABVX, AXSM, and RNA HeadlinesRecent News About These CompaniesEFG Asset Management North America Corp. Raises Stock Holdings in Avidity Biosciences, Inc. $RNASeptember 6 at 8:45 AM | marketbeat.comEric Mosbrooker Sells 6,563 Shares of Avidity Biosciences (NASDAQ:RNA) StockSeptember 6 at 8:10 AM | insidertrades.comAvidity Biosciences, Inc. $RNA Shares Sold by Cormorant Asset Management LPSeptember 6 at 7:45 AM | marketbeat.comAdage Capital Partners GP L.L.C. Has $63.35 Million Stock Position in Avidity Biosciences, Inc. $RNASeptember 5 at 6:08 AM | marketbeat.comAvidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeptember 5 at 6:02 AM | seekingalpha.comMPM Bioimpact LLC Has $21.08 Million Stake in Avidity Biosciences, Inc. $RNASeptember 4 at 7:02 AM | marketbeat.comFrazier Life Sciences Management L.P. Invests $15.50 Million in Avidity Biosciences, Inc. $RNASeptember 4 at 6:50 AM | marketbeat.comAvidity Biosciences CEO expects ‘lots of rumors’ about acquisition interestSeptember 4 at 2:30 AM | msn.comNorthern Trust Corp Sells 60,952 Shares of Avidity Biosciences, Inc. $RNASeptember 2, 2025 | marketbeat.comDriehaus Capital Management LLC Purchases 42,873 Shares of Avidity Biosciences, Inc. $RNAAugust 31, 2025 | marketbeat.comSiren L.L.C. Decreases Holdings in Avidity Biosciences, Inc. $RNAAugust 31, 2025 | marketbeat.comRafferty Asset Management LLC Sells 32,167 Shares of Avidity Biosciences, Inc. $RNAAugust 31, 2025 | marketbeat.comInsider Selling: Avidity Biosciences (NASDAQ:RNA) CEO Sells 25,000 Shares of StockAugust 30, 2025 | insidertrades.comInvesco Ltd. Purchases 193,376 Shares of Avidity Biosciences, Inc. $RNAAugust 28, 2025 | marketbeat.comAvidity Biosciences to Participate in Upcoming Investor ConferencesAugust 27, 2025 | prnewswire.comBI Asset Management Fondsmaeglerselskab A S Sells 52,463 Shares of Avidity Biosciences, Inc. $RNAAugust 27, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 295,275 Shares of Avidity Biosciences, Inc. $RNAAugust 26, 2025 | marketbeat.com771,158 Shares in Avidity Biosciences, Inc. $RNA Acquired by T. Rowe Price Investment Management Inc.August 26, 2025 | marketbeat.comRNA Stock Moves More Than 30% in a Week: What's Driving This Rally?August 25, 2025 | zacks.comNuveen LLC Invests $12.73 Million in Avidity Biosciences, Inc. $RNAAugust 24, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Insider Sells $102,451.20 in StockAugust 23, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUPH, ABVX, AXSM, and RNA Company DescriptionsAbivax NASDAQ:ABVX$88.03 +2.48 (+2.90%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$87.69 -0.34 (-0.39%) As of 09/5/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Aurinia Pharmaceuticals NASDAQ:AUPH$12.40 -0.13 (-1.04%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.42 +0.03 (+0.20%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Axsome Therapeutics NASDAQ:AXSM$125.17 +0.76 (+0.61%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$126.23 +1.06 (+0.85%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Avidity Biosciences NASDAQ:RNA$50.36 +1.89 (+3.90%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$50.18 -0.17 (-0.35%) As of 09/5/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
